Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ArmiVET
- Development stage
- Unknown
- Lead developer
- Armis Biopharma
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides
- Administration
- Topical
01
Overview
ArmiVET is a commercially marketed veterinary topical wound-care spray from Armis Biopharma. It is used for washing or rinsing surgical wounds, cuts, scrapes, sores, and skin irritations in animals, including use on skin, nose, ears, paws, hooves, fur, and hair. The proprietary, non-systemic formulation is intended to cleanse and debride wounds, moisturize damaged tissue, reduce local irritation and inflammation, and provide broad antimicrobial support. Armis Biopharma positions the product within its Veriox technology platform, which the company describes as a peracid/hydrogen peroxide-based antimicrobial and antitoxin platform. (armisbiopharma.com)
- Brand names
- ArmiVET
Beyond the preview
Go deeper on ArmiVET.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ArmiVET.